Trouble getting weight loss drugs covered by insurance? Here's what to know
Millions of Medicare beneficiaries continue to face insurance barriers and legal disputes over federal price negotiations for GLP-1 weight loss medications. While some local governments, such as DeKalb County, protect coverage, medical experts warn that these drugs can cause uncontrollable body movements. This side effect can leave patients unable to work, sleep, or perform basic daily activities. Access remains a primary point of contention as patients struggle to secure coverage for these treatments.
What changed
No new information regarding weight loss drug coverage or GLP-1 side effects was provided in the latest source material.
Live updates
-
Insurance barriers persist for GLP-1 weight loss drugs
Millions of Medicare beneficiaries continue to face insurance barriers and legal disputes over federal price negotiations for GLP-1 weight loss medications. While some local governments, such as DeKalb County, protect coverage, medical experts warn that these drugs can cause uncontrollable body movements. This side effect can leave patients unable to work, sleep, or perform basic daily activities. Access remains a primary point of contention as patients struggle to secure coverage for these treatments.
Why it matters
GLP-1 drugs have become widely used for weight loss but are subject to complex insurance and federal pricing rules. The emergence of severe movement-related side effects adds a health risk to the existing financial struggle for access.
What to watch next
- Rulings on federal price negotiations for GLP-1 drugs
- Updates on Medicare coverage eligibility for weight loss medications
confidence 100%Sources used for this update (6)
- jen.jiji.com — Juventus, Locatelli's anxiety: injury against Milan, risk of surgery
- inews.co.uk — I left Cornwall for France – the scenery is better but life is extortionate
- inews.co.uk — I refused a student maintenance loan – now I can’t afford to go to lectures
- inews.co.uk — HMRC delays cost me £323 – hundreds of thousands of parents are at risk
- www.theglobeandmail.com — Dick’s Sporting Goods Has a Foot Locker Problem
- www.forbes.com — Brand Trust Ends Where Child Safety Fails
-
Experts Warn of Severe Side Effects Linked to Weight Loss Medications
Medical experts are warning of a little-known side effect from medications used by millions of Americans for weight loss that can cause uncontrollable body movements. The condition can be devastating, leaving some patients unable to sleep, work, or perform basic daily activities. This health risk emerges as access to GLP-1 drugs remains a point of contention, with some local governments like DeKalb County protecting coverage while millions of Medicare beneficiaries still face insurance barriers and legal disputes over federal price negotiations.
Why it matters
The accessibility of GLP-1 medications is currently divided between local policy victories and federal legal battles. While some employees have secured insured access, federal negotiations continue to impact millions of beneficiaries. The emergence of severe side effects adds a new layer of risk to the widespread adoption of these treatments.
Still unconfirmed
- A condition causing uncontrollable movements has been linked to medications taken by millions of Americans.
- The side effect can leave sufferers unable to work, sleep, or carry out ordinary daily activities.
What to watch next
- Clinical data identifying the specific mechanism of the uncontrollable movement side effect.
- Updates on federal price negotiations for weight loss treatments affecting Medicare beneficiaries.
confidence 70%Sources used for this update (13)
- www.dailymail.com — Katie was prescribed medication taken by millions of Americans... then a terrifying condition left her moving uncontrollably. Now, experts warn little-known side effect …
- inews.co.uk — Inside Meghan and Harry’s ultra luxe lifestyle – and the millions needed to fund it
- inews.co.uk — The Bologna alternative with beautiful architecture, great food and no crowds
- jen.jiji.com — Women's Volleyball European Championship, today the Italy-Turkey final - Live
- awaaz.co.nz — Opportunity out of Parliament in latest poll, as coalition retains power on back of ACT surge
- jen.jiji.com — Serie A, today Juventus-Milan 0-0 - Live
- www.dailymail.com — Millions of Aussies could get an extra $82 a week under Pauline Hanson's radical super shake-up
- jen.jiji.com — Fabio Grosso sacked by Fiorentina: he will no longer be the coach
- www.dailymail.com — Australian influencer with tanning addiction turns heads in a revealing mermaid outfit as she pulls up in a Corvette to go engagement ring shopping with her boyfriend
- awaaz.co.nz — Dunedin City Council rejects proposal to explore partnership with an Indian city
- inews.co.uk — One million pensioners to get £70 refund letter – what to do if you get one
- jen.jiji.com — With a complete spinal cord injury, they walk again, a milestone achieved by Made in Italy research
-
DeKalb County Board maintains insurance coverage for GLP-1 weight loss drugs
DeKalb County employees retain insured access to GLP-1 medications after the County Board voted 18-3 to reject a measure that would have restricted coverage. The decision follows concerns from board members like Rhonda Henke, who stated she felt uncomfortable singling out employees for taking a specific medication. This local victory for patient access occurs as millions of Medicare beneficiaries continue to face insurance barriers and legal disputes regarding federal price negotiations for similar weight loss treatments.
Why it matters
Weight loss drugs like Wegovy and Mounjaro are often subject to strict insurance hurdles. While lower doses can save patients nearly 1,000 pounds per year, many still struggle with high costs. Programs like Bridge have offered limited prescriptions for 50 dollars per month through CVS and Walgreens.
What is confirmed
- The DeKalb County Board voted 18-3 to maintain insured access to GLP-1s for employees.
- Rhonda Henke expressed discomfort with singling out employees for taking a specific medication.
What to watch next
- Outcome of federal price negotiation legal disputes for Medicare beneficiaries
- Updates on the expiration date for Bridge program prescription reductions
confidence 100%Sources used for this update (5)
- jen.jiji.com — Volleyball European Championship, today Italy-Poland semi-final: time and where to watch it live on free-to-air TV
- inews.co.uk — I cleared my £370,000 debt by raffling my house – it’s now my full-time job
- www.dailymail.com — Always struck down with a cold, cough or sore throat? There's probably a simple fix, says DR ELLIE, and it can be found in your local pharmacy
- insurancenewsnet.com — DeKalb County employees will still have insured access to GLP-1s
- inews.co.uk — How to take plant cuttings and save money next spring
-
Lower dose weight loss drugs match high strength results, study finds
Patients achieve similar weight loss using lower doses of medications such as Wegovy and Mounjaro compared to high strength versions. This dosage adjustment can save patients nearly 1,000 pounds per year. These findings emerge as millions of Medicare beneficiaries still face insurance barriers and legal disputes over federal price negotiations. While the Bridge program provided 200,000 users with prescriptions for 50 dollars per month through CVS and Walgreens, those reductions are subject to a deadline and cover only a small fraction of the eligible population.
Why it matters
Access to brand-name weight loss medications remains fragmented due to costs and insurance restrictions. The discovery that lower doses are equally effective offers a potential path to reduce financial burdens for patients. This is particularly significant for those currently excluded from insurance coverage or relying on temporary discount programs.
What is confirmed
- Two studies found that increasing the dosage of drugs like Wegovy and Mounjaro did not result in significantly greater weight loss.
- Lower dose fat jabs can save patients nearly 1,000 pounds a year.
- CVS and Walgreens filled 100,000 prescriptions each through the Bridge program at 50 dollars per month.
What to watch next
- Updates on the Bridge program deadline
- Changes to Medicare insurance coverage for brand-name weight loss drugs
- Clinical guidance on standardizing lower dose prescriptions
confidence 100%Sources used for this update (9)
- awaaz.co.nz — Beyond Bollywood: Why New Zealand musicians should be looking to India
- inews.co.uk — I’m a state deputy headteacher – here’s why I sent my children to private schools
- www.ynetnews.com — Dementia doesn’t always begin with memory loss: early warning signs to watch for
- inews.co.uk — I went in search of Britain’s best burgers – here are my 24 favourites
- jen.jiji.com — Meloni in Bari: "From today we are the longest-serving government. Italy is now taken seriously" - Live
- www.dailymail.com — Patients lose just as much weight on lower dose fat jabs as high strength - saving them nearly £1000 a year, study finds
- www.dailymail.com — BORIS JOHNSON: Burnham must get a grip and send reinforcements to the Falklands - NOW
- inews.co.uk — I saved a woman’s life on 9/11. Twenty-five years on, we finally met
- jen.jiji.com — "I'll call you back...", Meloni and her daughter's phone call during the rally - Video
-
Medicare beneficiaries face continued barriers to obesity drug access
Millions of Medicare beneficiaries remain unable to access brand-name weight loss medications due to insurance barriers and legal disputes over federal price negotiations. While CVS and Walgreens have each filled 100,000 prescriptions through the Bridge program for $50 per month, these cost reductions are subject to a deadline. Access remains fragmented as the 200,000 users who benefited from the program represent only a small fraction of the eligible population needing these treatments.
Why it matters
Federal price negotiations for medications are currently contested in court, complicating long-term pricing. The Bridge program serves as a temporary relief measure for eligible patients.
What to watch next
- The expiration date of the Bridge program cost-reduction benefit
- Court rulings regarding federal price negotiations for brand-name drugs
confidence 100%Sources used for this update (7)
- jen.jiji.com — Naples, McTominay undergoes surgery: here's when he'll return to the field
- jen.jiji.com — US Open, Musetti and Bellucci in the second round
- jen.jiji.com — European defense, Ischinger: "We are too small, the E5 format can be the solution" (3)
- awaaz.co.nz — ‘God’s decision’: Lucky change of plan saves New Zealand pilgrims from Nepal flood
- awaaz.co.nz — Priyanca Radhakrishnan takes petition seeking Peters’ removal as foreign minister to Parliament
- inews.co.uk — Bank of Dave: I know the one thing that could fix the state pension for everybody
- inews.co.uk — Is Israel seeking Trump’s backing to commit a war crime in Gaza?
-
Medicare Users Access Obesity Drugs via Bridge Program Amid Ongoing Barriers
CVS and Walgreens have each filled 100,000 prescriptions for obesity medications through the Bridge program, providing eligible Medicare beneficiaries with drugs for $50 per month. While 200,000 users have utilized this cost break, millions of others remain unable to access these medications. Access to brand-name weight loss drugs remains fragmented due to existing insurance barriers and legal disputes regarding federal price negotiations. The current cost-reduction benefit for Medicare users is subject to a deadline.
Why it matters
The Bridge program launched July 1 to increase the accessibility of obesity medications for Medicare beneficiaries. Systemic hurdles persist as legal battles over drug pricing continue. These barriers prevent a broader rollout of affordable brand-name options beyond the initial program participants.
What is confirmed
- CVS and Walgreens have each filled 100,000 prescriptions for obesity medications through the Bridge program.
- The Bridge program provides eligible Medicare beneficiaries with obesity drugs for $50 per month.
- The Bridge program launched on July 1.
Still unconfirmed
- The Medicare cost break for weight loss drugs has a deadline.
What to watch next
- Legal rulings on federal price negotiations for brand-name weight loss drugs
- Expiration date of the Bridge program cost break
- New data on insurance coverage rates for obesity medications
confidence 90%Sources used for this update (11)
- inews.co.uk — An expert guide to gardening through the ‘false autumn’
- jen.jiji.com — Serie A, today Cagliari-Inter: time, probable lineups and where to watch it
- inews.co.uk — The financial case against downsizing
- jen.jiji.com — Germany, knife attack at Rosenheim station: 31-year-old British woman killed
- jen.jiji.com — E-commerce: Amazon, Second Hand Deals Festival returns
- jen.jiji.com — Frank Matano has become a dad: "So grateful to have you in my life"
- finance.yahoo.com — 200,000 Medicare users sprint to CVS and Walgreens to snatch up $50 obesity drugs — millions more are still missing out
- inews.co.uk — I turn 55 this year and want to cut my working hours. Can I take money from my SIPP?
- inews.co.uk — I’m a cruise expert – this new boutique French sailing offers great-value luxury
- inews.co.uk — I want to retire at 58 – can my savings bridge the gap until I get my pension?
- jen.jiji.com — Inflation, August hit: +3.3%. Energy prices drive it up
-
Medicare Bridge Program fills 200,000 obesity drug prescriptions
CVS and Walgreens have each filled 100,000 prescriptions for obesity medications through the Bridge program. Launched July 1, the initiative provides eligible Medicare beneficiaries with these drugs for $50 per month to increase accessibility. Despite this early success, patients still face fragmented access to brand-name weight loss medications due to ongoing legal disputes over federal price negotiations and existing insurance barriers. No new data on insurance coverage or legal rulings has emerged to resolve these systemic hurdles.
Why it matters
Obesity medications are often subject to strict insurance restrictions, making them unaffordable for many. The Bridge program acts as a temporary relief measure for Medicare users. Federal drug price negotiations remain a point of legal contention between the government and pharmaceutical companies.
What to watch next
- Court rulings on federal drug price negotiations
- Expansion of the Bridge program to other pharmacy chains
- New insurance coverage mandates for obesity medications
confidence 100%Sources used for this update (12)
- inews.co.uk — We’re a family of three – the surprising way we save on the weekly shop
- jen.jiji.com — Trump: "Putin will not attack NATO territories" - Video
- jen.jiji.com — Record heat, scorching Friday: today red alert in 9 cities, Rome is also included
- laist.com — Federal fire fund lag
- jen.jiji.com — Vuelta a España, today seventh stage: schedule, route and where to watch it
- inews.co.uk — I bought my kitchen second hand on Facebook for £1,500 – here’s how you can too
- inews.co.uk — The affordable country with a Mediterranean coast and crowd-free Roman ruins
- jen.jiji.com — Drama in Palermo, two-year-old girl drowns in pool
- inews.co.uk — I can’t get rid of my mum’s retirement flat even after cutting the price by £190,000
- jen.jiji.com — Castellammare di Stabia, 75-year-old woman found dead on balcony: body partially carbonized
- inews.co.uk — I went to Canada for university – I saved £40,000 and found a job easily
- jen.jiji.com — MotoGp, today's qualifying and Sprint race Aragon GP: times and where to watch them on TV
-
Medicare obesity drug program sees high initial adoption
CVS and Walgreens report that they have each filled 100,000 prescriptions through the Bridge program, which offers eligible Medicare beneficiaries obesity medications for $50 per month. The program launched July 1 to improve access to weight loss drugs. While this specific initiative shows strong early uptake, the broader landscape for brand-name weight loss drugs remains fragmented due to ongoing insurance barriers and legal disputes over federal drug price negotiations.
Why it matters
Medicare's Bridge program aims to lower out-of-pocket costs for older adults facing high prices for obesity treatments. This follows legal battles, such as AstraZeneca's unsuccessful challenges to the U.S. government's drug price negotiation system. These efforts reflect a wider struggle to balance medication accessibility with pharmaceutical costs.
What is confirmed
- The Bridge program allows some Medicare beneficiaries to obtain obesity drugs for $50 a month.
- CVS and Walgreens have each filled 100,000 prescriptions via the Bridge program.
- The Bridge program began on July 1.
What to watch next
- Updated prescription volume data from other major pharmacy chains
- Further court rulings on the U.S. government's drug price negotiation program
confidence 100%Sources used for this update (11)
- jen.jiji.com — Roma-Fiorentina, goal disallowed for Hermoso and protests over Malen's goal: what happened
- inews.co.uk — I want to buy my high-rise council flat – will I struggle to get a mortgage on it?
- inews.co.uk — I picked up bedbugs at a UK airport hotel, and lost hundreds of pounds
- jen.jiji.com — North Korea, Trump: "Reduced exercises with Seoul, I have excellent relations with Kim"
- jen.jiji.com — Acquirente Unico, Moles: "Support for consumers at the heart of our mission"
- jen.jiji.com — Ranucci: "They have already tried to remove me, my conscience is clear" - Video
- inews.co.uk — We never wanted to get married – now we’re doing it to avoid an inheritance tax bill
- jen.jiji.com — Lunar eclipse on August 28, no risk to eyes: here's when and where to see it
- jen.jiji.com — Earthquake in Friuli, magnitude 3.3 tremor in the province of Udine during the night: fear but no damage
- jen.jiji.com — Accident with a holy water font in church, 6-year-old girl undergoes emergency aorta surgery in Bari
- www.kuow.org — Drugstores say Medicare's $50 obesity drug program is catching on
-
Insurance Challenges Persist for Obesity Medications
Patients continue to struggle with insurance coverage for brand-name weight loss drugs. While Medicare provides select medications to older adults for $50 per month, other barriers remain. Recent legal developments show AstraZeneca lost its second court battle against the U.S. government's drug price negotiation program, a system intended to lower costs for medications. Access remains fragmented, with some patients relying on subsidies while others face high out-of-pocket costs or legal hurdles regarding price negotiations.
Why it matters
The high cost of GLP-1 medications has created a divide in patient access based on insurance provider and age. Federal efforts to negotiate drug prices aim to reduce these costs but face ongoing legal challenges from pharmaceutical companies.
Still unconfirmed
- AstraZeneca lost its second legal battle against the U.S. government's drug price negotiation program.
What to watch next
- Further court rulings on the U.S. government's drug price negotiation program
- Updates on the legal availability of retatrutide
- Official data on the efficacy and tradeoffs of oral GLP-1 pills
confidence 70%Sources used for this update (9)
- jen.jiji.com — Serie A restarts, today Inter-Monza - Live
- inews.co.uk — William Hanson: My best purchase was my £180,000 Manchester flat when I was 20
- jen.jiji.com — Serie A, today Venezia-Lecce: time, probable lineups and where to watch it
- inews.co.uk — I’m an immigrant in limbo. Uni in the UK will cost me £250,000
- jen.jiji.com — INPS, 3 million young people use digital services
- inews.co.uk — I regret moving to London for my career – our rent was £2,350 a month
- jen.jiji.com — USA, fire threatens Reno in Nevada, evacuation warnings for nearly 90,000 people
- jen.jiji.com — Pierluigi Pardo defends Alessandro Vescini after Dazn gaffe: "Surreal controversy"
- www.statnews.com — Pharmalittle: We’re reading about Medicaid obesity-drug coverage, a Regenxbio gene therapy, and more
-
Insurance Access and Availability for Weight Loss Medications
Medicare continues to provide select weight loss drugs for $50 per month to older adults. While this subsidy improves access, patients must still monitor for side effects and drug interactions. Many individuals still face difficulties securing insurance coverage for brand-name medications. Additionally, the experimental drug retatrutide remains unavailable through legal channels despite appearing on grey markets. Recent mentions of GLP-1 pills suggest a shift in delivery methods, though specific tradeoffs for these oral versions remain undisclosed in current corroborated reports.
Why it matters
Weight loss drugs have seen a surge in demand, leading to insurance disputes and the rise of unregulated markets. The introduction of Medicare subsidies aims to lower costs for seniors. The transition from injectables to pills represents a potential shift in patient accessibility.
What to watch next
- Official release of GLP-1 pill tradeoff data
- Updates on legal availability of retatrutide
- Changes to Medicare weight loss drug subsidies
confidence 100%Sources used for this update (8)
- jen.jiji.com — Mps, offers for Bpm and Banca Generali for approximately 34 billion
- jen.jiji.com — Militello, swastika in the municipal park. Musumeci condemns: "Cowardly act, clarify immediately"
- consent.yahoo.com — GLP-1 pills are finally here. Here's the tradeoff nobody's advertising
- inews.co.uk — The welcoming pub-filled city with a medieval cathedral and Roman heritage
- jen.jiji.com — Sweden, attacks a school armed with a machete: several injured
- inews.co.uk — William Hanson: My best purchase was my £180,000 Manchester flat when I was 20
- jen.jiji.com — Dutch GP, sprint race today - Live
- inews.co.uk — I wore Meta glasses on a night out – the reaction filled me with shame
-
Medicare adds coverage for select weight loss drugs
Medicare now covers select weight loss drugs for $50 per month. This development provides a subsidized option for older adults, though medical guidance suggests these patients must evaluate potential drug interactions and side effects. This occurs as some patients continue to struggle with insurance access for brand-name medications and an experimental drug called retatrutide has appeared on a grey market despite not being legally available to the public.
Why it matters
Insurance providers have recently removed coverage for several brand-name weight loss drugs. This shift left millions of people without treatment access between 2025 and 2026. The current environment includes a rise in unregulated drug sales and funding cuts to healthcare safety agencies.
What is confirmed
- Medicare covers select weight-loss drugs for $50 per month.
Still unconfirmed
- The drug retatrutide is being sold on a grey market while remaining in the experimental phase.
- The Trump administration shut down a patient safety agency through funding cuts.
What to watch next
- Reports on the volume of older adults enrolling in the Medicare weight loss drug program
- Regulatory actions against the grey market sale of retatrutide
confidence 70%Sources used for this update (5)
- www.aol.com — I Tried GLP-1s For 8 Weeks—Here's My Honest Experience
- www.aarp.org — Medicare Now Covers Some Weight Loss Drugs — but Older Adults Should Weigh the Risks
- www.northcarolinahealthnews.org — Trump has quietly throttled an agency devoted to the safety of American healthcare
- www.thetechedvocate.org — The Chilling Truth: Why the ‘Godzilla’ Weight-Loss Drug Is a Recipe for Disaster
- www.newsday.com — Newsday on Instagram
-
Medicare Now Covers Select Weight-Loss Drugs as Grey Market Risks Grow
Medicare now provides coverage for certain weight-loss medications at a cost of $50 per month. This development follows a period where millions of patients lost insurance access to brand-name treatments between 2025 and 2026. While some coverage has returned, health warnings are increasing regarding the use of experimental drugs. Retatrutide, an experimental weight-loss medication not legally available to the public, is currently being traded on a grey market, posing significant health concerns to users seeking alternatives to covered prescriptions.
Why it matters
Patients have struggled to secure insurance for GLP-1 medications as many plans removed coverage for brand-name drugs. The emergence of unregulated markets for experimental drugs increases patient risk. This occurs as the Trump administration has cut funding to a patient safety agency.
What is confirmed
- Medicare covers select weight-loss drugs for $50 per month.
- The Trump administration shut down a patient safety agency through funding cuts.
Still unconfirmed
- Retatrutide is being bought and sold on a grey market despite being in an experimental phase and not legally available to the public.
What to watch next
- Official FDA status or legal availability of retatrutide
- Updates on the funding status of the patient safety agency
- Changes to Medicare coverage tiers for GLP-1 medications
confidence 90%Sources used for this update (5)
- www.aol.com — I Tried GLP-1s For 8 Weeks—Here's My Honest Experience
- www.aarp.org — Medicare Now Covers Some Weight Loss Drugs — but Older Adults Should Weigh the Risks
- www.northcarolinahealthnews.org — Trump has quietly throttled an agency devoted to the safety of American healthcare
- www.thetechedvocate.org — The Chilling Truth: Why the ‘Godzilla’ Weight-Loss Drug Is a Recipe for Disaster
- www.newsday.com — Newsday on Instagram
-
Insurance Coverage Challenges for GLP-1 Weight Loss Drugs
Patients continue to face difficulties securing insurance for weight loss medications. Many plans have removed coverage for specific brand-name drugs. New data shows millions of people lost access to these treatments between 2025 and 2026.
Still unconfirmed:
- Between 2025 and 2026, 12 million people were on plans that dropped coverage for Zepbound.
- Between 2025 and 2026, 12 million people had plans that dropped Wegovy.
- Medicare started coverage for GLP-1 drugs on July 1.
confidence 50%Sources used for this update (4)
-
Insurance Coverage Challenges for GLP-1 Weight Loss Drugs
Patients face significant hurdles obtaining insurance coverage for GLP-1 weight loss medications. While some large employers maintain coverage, others are cutting benefits or utilizing telehealth providers to control costs. New pill versions of these drugs may further complicate employer-sponsored insurance reimbursement.
What's confirmed:
- Weight loss drugs generally cost about $1,100 per month without insurance or discounts.
- Manufacturer discounts and insurance can reduce monthly costs to between $0 and $25.
- Some employers are using telehealth providers to limit GLP-1 drug expenses.
Still unconfirmed:
- SHRM members are reducing mental health benefits to fund GLP-1 drugs.
- Physicians' insurance plans do not cover GLP-1s for obesity.
- Medicare GLP-1 Bridge plan will cost older adults $50 a month starting July 1.
confidence 80%Sources used for this update (18)
- Trouble getting weight loss drugs covered by insurance? Here's what to know
- With Mass. cutting weight loss drug coverage, patients scramble to afford prescriptions
- Eli Lilly’s hottest drugs face a quiet new threat
- Even Physicians’ Insurance Plans Don’t Cover GLP-1s for Obesity
- SHRM members ‘struggling’ to fund GLP-1 drugs, pulling back on mental health benefits
- GLP-1 Coverage: Solutions for Managing Weight-Loss Drug Costs
- Will employers still cover GLP-1s for weight loss?
- Companies turn to telehealth providers to limit GLP-1 drug costs
- Most large employers hold steady on GLP-1 coverage, for now
- The economics of obesity drugs: Reimbursement, pricing power, and the next healthcare cost debate
- Ozempic has waged a war on America’s junk food. Disrupting a trillion-dollar industry
- Less Volume, More Premium: Post-Ozempic Economics Are Killing The Quantity Model